Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,538 signal articles · 209 in last 24h · 133,463 total before filter · latest 15m ago
209last 24h
1100last 7d
179● bullish (7d)
124● bearish (7d)
208publishers
AllMacro269Earnings388M&A73Regulatory28Product10Analyst16
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
Super Micro Rises 4% Ahead of Earnings; HPE Gains 4%, Dell Climbs 3% as AI Server Stocks Advance
24/7 Wall St.24d agobullish
Super Micro Rises 4% Ahead of Earnings; HPE Gains 4%, Dell Climbs 3% as AI Server Stocks Advance

Shares of Super Micro Computer (NASDAQ:SMCI) are up 4% to $32.48 in Monday morning trading, leading a broad bid across AI server names heading into the company’s fiscal Q4 2026 earnings report. Hewlett Packard Enterprise (NYSE:HPE) stock is climbing 4% to $55.20, and Dell Technologies (NYSE:DELL) shares are advancing 3% to $468.67. The action is ... Super Micro Rises 4% Ahead of Earnings; HPE Gains 4%, Dell Climbs 3% as AI Server Stocks Advance

DraftKings After Earnings: Buy, Hold, or Run?
24/7 Wall St.24d agobullish
DraftKings After Earnings: Buy, Hold, or Run?

DraftKings just posted its worst margin quarter in years while simultaneously launching a business growing five times faster than its core sportsbook ever did. One of those stories is going to dominate the next 90 days, and the NFL season will decide which.

Cigna Group (CI) Reports Q2 Earnings And Buybacks, Is It Trading At A Discount?
Simply Wall St.25d agobullish
Cigna Group (CI) Reports Q2 Earnings And Buybacks, Is It Trading At A Discount?

Q2 earnings and buybacks put Cigna Group in focus Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total...

Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?
Simply Wall St.25d agobullish
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?

Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising full year revenue guidance and updating progress on its share repurchase programs. For the quarter ended June 30, 2026, revenue was reported at US$481 million compared with US$325.72 million for the same period a year earlier. Net income for the quarter was US$229.91 million compared with US$165.16 million a year ago. Basic...